NeuroPace (NPCE)

NeuroPace Stock Analysis & Ratings

NPCE Stock Chart & Stats

Day’s Range$5.97 - $5.97
52-Week Range$5.08 - $25.75
Previous Close$6
Average Volume (3M)58.91K
Market Cap$146.89M
P/E Ratio-3.8
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score1
EPS (TTM)-1.59



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $5.08 and its highest was $25.75 in the past 12 months.
    What is NeuroPace’s market cap?
    NeuroPace’s market cap is $146.89M.
      What is NeuroPace’s price target?
      The average price target for NeuroPace is $9.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $15.00 ,the lowest forecast is $6.00. The average price target represents 64.15% Increase from the current price of $5.97.
        What do analysts say about NeuroPace?
        NeuroPace’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is NeuroPace’s upcoming earnings report date?
          NeuroPace’s upcoming earnings report date is Aug 11, 2022 which is in 76 days.
            How were NeuroPace’s earnings last quarter?
            NeuroPace released its earnings results on May 12, 2022. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.442 by -$0.028.
              Is NeuroPace overvalued?
              According to Wall Street analysts NeuroPace’s price is currently Undervalued.
                Does NeuroPace pay dividends?
                NeuroPace does not currently pay dividends.
                What is NeuroPace’s EPS estimate?
                NeuroPace’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does NeuroPace have?
                NeuroPace has 24,610,000 shares outstanding.
                  What happened to NeuroPace’s price movement after its last earnings report?
                  NeuroPace reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.442. Following the earnings report the stock price went down -1.757%.
                    Which hedge fund is a major shareholder of NeuroPace?
                    Currently, no hedge funds are holding shares in NPCE


                    NeuroPace Stock Analysis

                    Smart Score
                    Price Target
                    ▲(64.15% Upside)
                    Moderate Buy
                    The NeuroPace stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description


                    NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis